Comparative Pharmacology
Head-to-head clinical analysis: MEFLOQUINE HYDROCHLORIDE versus SOVUNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEFLOQUINE HYDROCHLORIDE versus SOVUNA.
MEFLOQUINE HYDROCHLORIDE vs SOVUNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mefloquine is a quinoline antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown but is thought to involve forming toxic heme complexes or inhibiting heme polymerase, leading to parasite death.
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
250 mg (1 tablet) orally once weekly for prophylaxis; 1250 mg (5 tablets) as a single oral dose for treatment of uncomplicated malaria.
400 mg orally once daily with food.
None Documented
None Documented
~2-4 weeks (terminal half-life); clinical context: long half-life allows weekly dosing for prophylaxis, but accumulation can occur with repeated doses.
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
~83% (fecal/biliary), ~9% (renal unchanged), ~2.5% (renal as metabolite).
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Category A/B
Category C
Antimalarial
Antimalarial